GLP-1 Maintenance Dose: Staying on Treatment Long Term

Educational, not medical advice

This content is for general information only. It is not medical advice, a diagnosis, or a treatment plan. Beema Health's live clinical offering is telehealth medical weight-loss. Beema Health serves patients located in the United States only. It is not an international service. Licensed providers can evaluate adults in all 50 US states through telehealth. A licensed clinician reviews each intake and decides whether any medication is appropriate. Completing an online intake does not guarantee a prescription. Compounded semaglutide is not FDA-approved and is considered only when legally available and clinically appropriate. Compounded tirzepatide is not FDA-approved and is considered only when legally available and clinically appropriate. They are not the same as FDA-approved branded products. This library does not promise weight-loss results, show before-and-after photos, or collect health information.

Maintenance means a labeled long-term dose, not a finish line

After weeks of titration, many GLP-1 and dual-agonist labels name one or more maintenance strengths. That is the dose intended for ongoing treatment when the indication still applies and the medicine is tolerated. It is closer to how blood-pressure or cholesterol medicines are used than to a two-week antibiotic course.

This article is educational, not medical advice. Prescription required. Beema Health does not sell branded Wegovy or Zepbound. Completing telehealth intake does not guarantee a prescription. Weight loss is not guaranteed.

Examples of labeled maintenance ranges

Wegovy injection: for adult weight reduction, 1.7 mg or 2.4 mg weekly (2.4 mg recommended), with additional adult options on the current label after 2.4 mg is tolerated. Tablets: 25 mg once daily after escalation. Ozempic (diabetes): maintenance is selected for glycemic (and, where indicated, kidney) goals, often 0.5 to 2 mg weekly, not the Wegovy 2.4 mg target.

Zepbound: 5, 10, or 15 mg weekly for weight reduction; 10 or 15 mg weekly for OSA in adults with obesity. Mounjaro: diabetes maintenance up to 15 mg weekly in adults. Saxenda: 3 mg daily if tolerated.

Those numbers are not interchangeable across brands. See Wegovy dosing and Zepbound dosing for the climb that precedes maintenance.

What STEP 4 showed when semaglutide continued or stopped

STEP 4 gave adults with overweight or obesity 20 weeks of semaglutide, then randomized those who reached 2.4 mg to continue 2.4 mg or switch to placebo for 48 more weeks, with lifestyle intervention throughout. People who continued generally lost more weight after randomization. People switched to placebo regained a large share of what they had lost during the run-in.

The trial is one reason clinicians talk about obesity medicines as long-term therapy. It is not a threat. It is a measurement of what appetite and energy-balance biology tend to do when the drug is withdrawn.

What SURMOUNT-4 showed with tirzepatide

SURMOUNT-4 used 36 weeks of open-label tirzepatide, then randomized participants to continue tirzepatide or receive placebo for 52 weeks. Continuation preserved much more of the weight reduction. Placebo was followed by substantial regain from the randomization point, though some net loss from week 0 often remained.

Together with STEP 4, the message is consistent across two different approved molecules: stopping is a medical decision with expected weight change, not a moral failure.

How clinicians choose among maintenance options

Choice inside a label (5 versus 15 mg tirzepatide, 1.7 versus 2.4 mg semaglutide) weighs gastrointestinal tolerability, comorbidities, other drugs, and treatment goals (weight, OSA, cardiovascular risk reduction, glucose). More milligrams is not automatically 'better' if the person cannot eat or is dehydrated.

Follow-up visits exist to check heart rate, mood and support needs, gallbladder or pancreas warning symptoms, nutrition (including protein and muscle), and whether the indication still holds. Maintenance is not a set-and-forget calendar reminder.

When maintenance ends

Reasons to stop or change include pregnancy, intolerable adverse reactions, pancreatitis, supply problems, a new diagnosis that is a contraindication, or a shared decision that the benefit no longer outweighs the burden. Plan the next step: another labeled medicine, a slower off-ramp if the clinician uses one, and nutrition support. See stopping GLP-1 and rebound weight gain after GLP-1.

Beema Health's medical weight-loss overview describes how an online visit works if you are exploring telehealth care. It is not a promise of lifelong branded maintenance pens.

Frequently asked questions

What is a GLP-1 maintenance dose?

It is the labeled long-term dose after the starting and escalation pens (or tablets) are finished, chosen from options on that product's prescribing information. Examples include Wegovy 1.7 or 2.4 mg weekly (2.4 mg usually recommended) and Zepbound 5, 10, or 15 mg weekly for weight reduction. It is not a do-it-yourself fraction of a pen.

How long do people stay on a maintenance dose?

Obesity pharmacotherapy is generally treated as chronic care when the medicine remains appropriate. STEP 4 and SURMOUNT-4 showed that switching from active drug to placebo after a successful lead-in led to substantial weight regain compared with staying on medicine. Duration is individualized. There is no universal 'stop at one year' rule on the labels.

Can the maintenance dose go down later?

Sometimes a clinician reduces to another labeled strength because of side effects, or increases within the labeled range if more effect is needed and tolerated (for example, certain Wegovy adult options on the current label). Unofficial tapering without a plan is different from a documented dose change. See stopping GLP-1 if the question is really about discontinuation.

Is the maintenance dose the same as the starter dose?

No. Starter doses (Wegovy 0.25 mg, Zepbound 2.5 mg, Ozempic 0.25 mg, Mounjaro 2.5 mg, Saxenda 0.6 mg) are for initiation. Using them as forever-doses is not how the large efficacy trials were designed.

Does staying on a GLP-1 guarantee the weight stays off?

No. Even on maintenance treatment, weight can plateau or rebound if calories, activity, other medicines, or health conditions change. Trial averages are not promises. Lifestyle measures remain part of labeled use for weight-management products.

Does Beema Health keep people on branded maintenance pens?

Beema Health does not dispense Wegovy, Zepbound, or other brands discussed here. Ongoing care, if a Beema-network clinician prescribes a treatment Beema offers, is provider-directed after intake. Completing a visit does not guarantee a prescription or indefinite treatment.

Sources

Related education

Program pages

These pages describe Beema's live medical weight-loss offering. They are commercial pages, not this educational article.

Beema's live offering is medical weight-loss care

Licensed providers can evaluate adults in all 50 US states through telehealth. Beema Health serves patients located in the United States only. It is not an international service. A licensed clinician reviews each intake and decides whether any medication is appropriate. Completing an online intake does not guarantee a prescription. Compounded semaglutide is not FDA-approved and is considered only when legally available and clinically appropriate. Compounded tirzepatide is not FDA-approved and is considered only when legally available and clinically appropriate.

Beema Health is a LegitScript-certified website. Certification means the certified site is monitored against LegitScript's healthcare merchant standards. It is not an endorsement of Beema's products, not a statement that compounded medication is safe or FDA-approved, and not a claim about competitors. Beema Health has obtained Google's healthcare certification for prescription-drug advertising in the United States. That certification is about advertising eligibility. It is not a Google endorsement of Beema, of any medication, or of any clinical outcome.

Get Started

GLP-1 maintenance dose: staying on treatment after titration